Senseonics Holdings, Inc. (SENS) Q4 2025 Earnings Call Transcript
Senseonics Holdings (SENS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.4 per share a year ago.
Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration,
Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.
The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is w
The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is w
Shares of Senseonics Holdings, Inc. (NYSE: SENS - Get Free Report) have been assigned a consensus rating of "Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings r
Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Senseonics stock jumps after Eversense 365 wins CE Mark, expanding Europe access for its one-year CGM and strengthening the long-term growth outlook.
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuo
Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.
twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM
Senseonics Holdings, Inc. (NYSE: SENS - Get Free Report) has been given an average recommendation of "Buy" by the six analysts that are covering the company, MarketBeat.com reports. One equities resea
HBK Sorce Advisory LLC bought a new position in shares of Senseonics Holdings, Inc. (NYSE: SENS) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE